DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the initiation of a Phase 2a proof-of-concept clinical trial to test the efficacy of its AGS-004 therapy in improving immune control of viral replication in HIV-infected adults. AGS-004 is a product of the Company’s Arcelis™ technology, a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The target population for the study is HIV-1 infected patients with durable viral suppression from active antiretroviral therapy (ART).
